A Long-Term Observational, Retrospective Cohort Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice in the United States and Europe First published 06/01/2023 Last updated 16/04/2024 EU PAS number:EUPAS50402 Study Planned